2003
DOI: 10.1016/s0002-8703(03)00260-6
|View full text |Cite
|
Sign up to set email alerts
|

Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
21
0
3

Year Published

2004
2004
2014
2014

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 68 publications
(26 citation statements)
references
References 39 publications
2
21
0
3
Order By: Relevance
“…While a small production of MP at the local site of plaque rupture during PCI in stable patients cannot be excluded, as we have not measured MP in the coronary sinus, it should also be considered that Inoue's patients, differently from ours, were not treated with high-dose clopidogrel and statins, which may reduce the release of MP. [30][31][32] Our study supports the accumulating evidence that MP are independent markers of increased risk of cardiovascular events in high-risk patients, 33,34 and that they are significantly higher in ACS than in SA, 7,8 raising the question of whether MP should be used as biomarkers for early prediction (or detection) of ACS as already suggested by others. 8 In our opinion, however, MP are not ready to be used as a biomarker.…”
Section: Discussionsupporting
confidence: 87%
“…While a small production of MP at the local site of plaque rupture during PCI in stable patients cannot be excluded, as we have not measured MP in the coronary sinus, it should also be considered that Inoue's patients, differently from ours, were not treated with high-dose clopidogrel and statins, which may reduce the release of MP. [30][31][32] Our study supports the accumulating evidence that MP are independent markers of increased risk of cardiovascular events in high-risk patients, 33,34 and that they are significantly higher in ACS than in SA, 7,8 raising the question of whether MP should be used as biomarkers for early prediction (or detection) of ACS as already suggested by others. 8 In our opinion, however, MP are not ready to be used as a biomarker.…”
Section: Discussionsupporting
confidence: 87%
“…Similar trends have been reported in the recent PLUTO-CHF trial, which was designed almost identically with the index study but in a heart failure cohort. 10 It was expected that clopidogrel specifically targeting ADP platelet receptor would inhibit aggregation induced by this particular agonist and that clopidogrel would not affect arachidonic acidinduced aggregation already strongly inhibited by aspirin by modulating prostanoid metabolism. On the other hand, significant inhibition of collagen-induced aggregation after 1 month of combination therapy has been never reported in poststroke patients but is supported by the platelet data from the patients undergoing coronary interventions.…”
Section: Discussionmentioning
confidence: 99%
“…Their release by cell lysis, exocytosis of nucleotide-containing granules, and efflux through membrane transport proteins causes their concentrations in extracellular fluids to increase into micromolar ranges, and higher concentrations are probably achieved at cell-cell synapses (1). The key role for ADP and its receptors in vascular biology and platelet aggregation in vivo is well established by studies with P2Y1 and P2Y12 receptornull mice (12,13) and is validated in humans by the clinical efficacy of P2Y1 receptor antagonists as antiplatelet agents (41,42). The constitutive perivascular location of MCs throughout the body and their abundance in atherosclerotic plaques probably permit their exposure to endothelial-and platelet-derived nucleotides in vivo (43).…”
Section: Discussionmentioning
confidence: 99%